Endo International plc

305 articles about Endo International plc

• Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at The Aesthetic Meeting 2021

  4/29/2021

  Endo International plc (NASDAQ: ENDP) announced today that data relevant to the use of Endo Aesthetics' Qwo ® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during The Aesthetic Meeting 2021 .

• Endo Implements Board Succession Plan

  4/27/2021

  Mark Barberio appointed Chairman of the Board of Directors effective at 2021 Annual General Meeting

• Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes - Mar 11, 2021

  3/11/2021

  Endo International plc announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. and Endo U.S. Inc. priced $1.295 billion aggregate principal amount of 6.125% senior secured notes due 2029 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $295.0 million over the previously contemplated offering amount.

• Endo Appoints Jennifer M. Chao to Board of Directors

  2/17/2021

  Endo International plc announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately.

• Endo to Participate at J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference

  2/17/2021

   Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference on Monday, March 1, 2021 at 9:15 a.m. ET .

• Endo to Announce Fourth-Quarter and Full-Year 2020 Financial Results

  1/26/2021

  Endo International plc (NASDAQ: ENDP) will announce its fourth-quarter and full-year 2020 financial results on February 25, 2021 after the market closes and members of its senior management team will host a conference call and webcast on February 26, 2021 at 7:30am ET before the U.S. financial markets open. The dial-in nu

• Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

  1/5/2021

   Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all c

• Endo Aesthetics Launches "Really Cellulite" Campaign

  1/5/2021

  Endo International plc announced that its subsidiary, Endo Aesthetics LLC, launched an unbranded campaign designed to eliminate the shame and misinformation relating to cellulite.

• Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States

  1/4/2021

  Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza ® (lubiprostone) 8 mcg and 24 mcg capsules. "This partnership brings the first Amitiza ® generic to patients—giving them a cost-e

• Endo to Participate at J.P. Morgan 39th Annual Healthcare Conference

  12/18/2020

  Endo International plc announced that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. EST.

• Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer

  11/18/2020

  Endo International plc announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the previously announced tender offer by Beta Acquisition Corp...

• 

  Endo International Slashes 560 Jobs in Restructuring Plan Announced Following M&A Activity

  11/6/2020

  Shares of Endo International are up more than 5% after the company announced positive earnings Thursday and also announced a new restructuring plan.

• Endo Reports Third-Quarter 2020 Financial Results And Raises Full Year 2020 Financial Guidance

  11/5/2020

  Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2020.

• Endo Announces Strategic Actions to Further Position the Company for Long-Term Success

  11/5/2020

  Endo International plc (NASDAQ: ENDP) today announced the initiation of several strategic actions to further optimize the Company's operations and increase overall efficiency. These actions are expected to generate significant cost savings that will be reinvested,

• Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

  11/2/2020

  Isofol Medical AB, is pleased to announce a definitive license agreement with Endo Ventures Limited, a subsidiary of Endo International plc plc, for the registration and commercialization of arfolitixorin on an exclusive basis in Canada.

• Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.

  11/2/2020

  Endo International plc announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp., has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share of BioSpecifics Technologies Corp., at a price of $88.50 per Share, net to the holder in cash, without interest and less any applicable withholding taxes.

• Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™

  10/19/2020

  - Endo International plc (NASDAQ: ENDP) today announced it has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp. (NASDAQ: BSTC), a commercial-stage biopharmaceutical company, for $88.50 in cash per share, or an estimated enterprise

• BioSpecifics to be Acquired by Endo Pharmaceuticals

  10/19/2020

   BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo International plc (NASDAQ: ENDP) will acquire BioSpecifics for an estimated

• Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)

  10/9/2020

  Endo International plc (NASDAQ:ENDP) today announced that data relevant to the use of Endo Aesthetics' Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women will be featured during the American Society for Dermatologic Surgery's Annual Meeting (ASDS).

• Endo to Announce Third Quarter 2020 Financial Results

  10/7/2020

   Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2020 financial results on November 5, 2020 after the market closes and members of its senior management team will host a conference call and webcast on November 6, 2020 at 7:30am EST .